AC Immune SA (ACIU) Form 6-K — Jun 11, 2026
AC Immune SA held its Annual General Meeting on June 11, 2026, where shareholders approved the 2025 financial statements, which reported an IFRS net loss of CHF 70.4 million and statutory net loss of CHF 67.6 million. The company’s accumulated losses increased to CHF 424.4 million, reflecting its ongoing clinical-stage burn rate, though it maintains a cash position of CHF 74.8 million (approx. USD 94 million) providing a runway into Q4 2027. Shareholders endorsed the compensation report and approved maximum aggregate compensation caps of CHF 1.03 million for the Board and CHF 6.74 million for Executive Management for the upcoming period.
Key figures
- Cash Position
- 74800000
- Accumulated losses
- 424441000
- Shares outstanding
- 102000000
- Exec compensation max
- 6742000
- Board compensation max
- 1029000
- Capital band upper limit
- 2862500
- Employee benefit capital
- 150000
- Annual cash burn guidance
- CHF 55m - 65m
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.